Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
AbstractObjectivesThe aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection.Trial DesignThis is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and clinical outcome assessor.ParticipantsEligible participants include adults ( ≥ 18 years) with evidence of SARS-CoV-2 infection by PCR test of nasopharyngeal or oropharyngeal swab within 14 days of randomization, evidence of infiltrates on chest radiography, peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air,...
Source: Trials - June 7, 2020 Category: Research Source Type: clinical trials
Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial
This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients.Trial designProspective, randomized (1:1 ratio), double blind study with parallel group design.ParticipantsHospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Computed tomography scan involvement compatible with COVID-19 pneumonia. The patients are not severely hypoxic, do not need intubation or invasive oxygenation.Exclusion criteria: known hypersensitivity to colchicine; known hepatic failure; estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m2 (by th...
Source: Trials - June 4, 2020 Category: Research Source Type: clinical trials
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial
This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services.Intervention and comparatorCOVID-19 confirmed patients will be randomly assigned to one of three groups, with 20 patients in each. The first group (Arm 1) will receive Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon- β 1a (Recigen), the second group (Arm 2) will be administered Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon-β 1b (Ziferon), and the control group (Arm 3) will be treated by Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra).Main outcomesTime t...
Source: Trials - June 2, 2020 Category: Research Source Type: clinical trials
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: " The Hope Coalition - 1 "
Conditions: COVID-19; Coronavirus Infection; Virus Disease; Acute Respiratory Infection; SARS-CoV Infection Interventions: Drug: Hydroxychloroquine Sulfate Tablets; Drug: Lopinavir/ Ritonavir Oral Tablet; Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets; Drug: Placebo Sponsors: Cardresearch; Cytel Inc.; Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
Conditions: Pneumonia, Viral; Cytokine Storm Interventions: Radiation: Ultra-Low-dose radiotherapy; Device: ventilatory support with oxygen therapy; Drug: Lopinavir/ritonavir; Drug: Hydroxychloroquine; Drug: Azithromycin; Drug: Piperacillin/tazobactam; Drug: Low molecular weight heparin; Drug: Corticosteroid injectio n; Drug: Tocilizumab Sponsors: Fundacion GenesisCare; Hospital La Milagrosa; Hospital Vithas Valencia Consuelo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 19, 2020 Category: Research Source Type: clinical trials
